14 recruiting, 6 terminated, 5 completed, 4 not yet recruiting. 22 Phase 2, 13 Phase 1, 3 Phase 3, 2 Early Phase 1.
Follow Metastatic Clear Cell Renal Cell Carcinoma: new trials by email Literature Review of Metastatic Clear Cell Renal Cell Carcinoma trials Research Report on Metastatic Clear Cell Renal Cell Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging - Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8 | Phase 2 | Not yet recruiting | Fred Hutchinson Cancer Center | 50 | 2026-12-01 | 2026-09-17 |
| Zanzalintinib and MO-03 for the Treatment of Metastatic Renal Cell Cancer After Progression on Immunotherapy Biospecimen Collection, Bone Scan, C. butyricum CBM 588 Probiotic Strain Capsule Formulation MO-03 - Metastatic Clear Cell Renal Cell Carcinoma, Stage IV Renal Cell Cancer AJCC v8 | Phase 2 | Not yet recruiting | City of Hope Medical Center | 34 | 2026-11-28 | 2026-05-11 |
| Phase I Study Evaluating 161Tb-PSMA Therapy in Adult Patients With Metastatic Clear Cell Renal Cell Carcinoma 161Tb-PSMA-1 (radiopharmaceutical) - Metastatic Clear Cell Renal Cell Carcinoma | Phase 1 | Not yet recruiting | Centre Leon Berard | 26 | 2026-11-01 | 2026-09-18 |
| Casdatifan for the Treatment of Refractory Metastatic Clear Cell Renal Cell Carcinoma casdatifan - Refractory Clear Cell Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma | Phase 1 | Recruiting | Vanderbilt-Ingram Cancer Center | 12 | 2026-09-21 | 2026-09-25 |
| TACTIC-RCC: Toripalimab Plus Axitinib Induction With Selective Deferred Cytoreductive Nephrectomy in TLS-Positive Advanced Clear Cell Renal Cell Carcinoma Toripalimab, Axitinib, Deferred Cytoreductive Nephrectomy - Metastatic Clear Cell Renal Cell Carcinoma, Advanced Clear Cell Renal Cell Carcinoma | Phase 2 | Not yet recruiting | Fudan University | 30 | 2026-08-20 | 2026-08-20 |
| RP2 and Tivozanib for the Treatment of Metastatic Renal Cell Cancer After Progression on Immunotherapy Biopsy Procedure, Biospecimen Collection, Computed Tomography - Advanced Clear Cell Renal Cell Carcinoma, Advanced Renal Cell Carcinoma | Phase 2 | Withdrawn | City of Hope Medical Center | 2026-08-11 | 2026-10-01 | |
| CD70-Targeted Immuno-PET/CT-Directed Free of Therapy Used for mccRCC Patients With IMDC Favorable or Intermediate Risk PD-1/PD-L1 ICI + VEGFR-TKI, Treatment pause - Metastatic Clear Cell Renal Cell Carcinoma | Phase 2 | Recruiting | Jinling Hospital, China | 75 | 2026-06-16 | 2026-08-11 |
| Imaging Study in Metastatic Clear Cell RCC. RYZ512 - Metastatic Clear Cell Renal Cell Carcinoma | Early Phase 1 | Recruiting | RayzeBio, Inc. | 10 | 2026-06-15 | 2026-10-13 |
| Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer Axitinib, Biospecimen Collection, Bone Scan - Advanced Clear Cell Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma | Phase 3 | Recruiting | SWOG Cancer Research Network | 718 | 2026-06-05 | 2026-06-11 |
| VSV-IFNβ-NIS With Ipilimumab and Nivolumab for the Treatment of Advanced or Metastatic Clear Cell Renal Cell Carcinoma Biopsy Procedure, Biospecimen Collection, Computed Tomography - Advanced Clear Cell Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma | Phase 2 | Recruiting | Mayo Clinic | 18 | 2026-04-21 | 2026-06-05 |
| Radiopharmaceutical Treatment of Advanced Kidney Cancer 177Lu-PSMA-617 - Metastatic Clear Cell Renal Cell Carcinoma | Phase 2 | Recruiting | European Organisation for Research and Treatment of Cancer - EORTC | 48 | 2026-04-07 | 2026-06-04 |
| Immunotherapy (Nivolumab and Ipilimumab) With and Without a Live Biotherapeutic Product (EXL01) for the Treatment of Metastatic Renal Cell Cancer Biospecimen Collection, Bone Scan, Computed Tomography - Advanced Clear Cell Renal Cell Carcinoma, Advanced Sarcomatoid Renal Cell Carcinoma | Phase 1 | Recruiting | City of Hope Medical Center | 33 | 2026-03-23 | 2026-07-16 |
| Safety and Efficacy of Yiwoxidan Anti (AK112) Monotherapy in Patients With Metastatic Renal Clear Cell Carcinoma Who Are Intolerant to TKI Treatment: a Prospective, Single Arm, Phase II Clinical Study Yivoximab - Renal Cell Carcinoma (RCC), Metastatic Clear Cell Renal Cell Carcinoma | Phase 2 | Enrolling by invitation | Sun Yat-sen University | 60 | 2025-11-01 | 2026-03-23 |
| PSMA Therapy and Immunotherapy in Kidney Cancer Pembrolizumab, 177Lu-PNT2002, (F-18)-DCFPyL - Metastatic Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma | Phase 1 / Phase 2 | Withdrawn | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2025-10-01 | 2025-08-19 | |
| Effects of Belzutifan on 89Zr-DFO-girentuximab PET Uptake in Patients With Renal Cell Carcinoma (RCC) Belzutifan, 89Zr-DFO-girentuximab, 89Zr-DFO-girentuximab PET - Metastatic Clear Cell Renal Cell Carcinoma | Phase 1 | Withdrawn | NYU Langone Health | 2025-09-15 | 2026-10-22 | |
| Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma Casdatifan, Cabozantinib, Placebo - Metastatic Clear Cell Renal Cell Carcinoma, Advanced Clear Cell Renal Cell Carcinoma | Phase 3 | Recruiting | Arcus Biosciences, Inc. | 720 | 2025-09-08 | 2026-09-29 |
| Inulin Gel in Combination With Ipilimumab and Nivolumab for the Treatment of Metastatic or Locally Advanced Kidney Cell Cancer, ICON Trial Biopsy, Biospecimen Collection, Computed Tomography - Locally Advanced Clear Cell Renal Cell Carcinoma, Locally Advanced Sarcomatoid Renal Cell Carcinoma | Phase 1 / Phase 2 | Recruiting | University of Michigan Rogel Cancer Center | 55 | 2025-08-15 | 2026-07-31 |
| Imaging of Solid Tumors Using 18F-TRX 18F-TRX, Positron Emission Tomography (PET)/Computerized tomography (CT), Tumor Biopsy - Solid Tumor, Solid Carcinoma | Phase 1 | Recruiting | Rahul Aggarwal | 56 | 2025-07-03 | 2026-07-23 |
| CBM588 Capsules in Combination With Nivolumab and Ipilimumab for the Treatment of Advanced Stage Kidney Cancer Biospecimen Collection, Bone Scan, CBM588 Capsules - Advanced Clear Cell Renal Cell Carcinoma, Advanced Renal Cell Carcinoma | Phase 1 | Recruiting | Osel, Inc. | 28 | 2024-06-19 | 2024-05-30 |
| Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform Biospecimen Collection, Tissue Collection - Early Stage Triple-Negative Breast Carcinoma, Metastatic Bladder Urothelial Carcinoma | Recruiting | Mayo Clinic | 324 | 2024-04-24 | 2026-03-12 |
Showing 20 of 38. Sign in to see all of them.
Clear-cell metastatic renal cell carcinoma (38) · Carcinoma, Renal Cell (25) · Neoplasm Metastasis (6) · Kidney Neoplasms (4) · Carcinoma, Non-Small-Cell Lung (2) · Carcinoma, Transitional Cell (2) · Colorectal Neoplasms (2) · Prostatic Neoplasms (2) · Uterine Cervical Neoplasms (2) · Carcinoma, Basal Cell (1) · Carcinoma, Hepatocellular (1) · Carcinoma, Merkel Cell (1) · Carcinosarcoma (1) · Endometrial Neoplasms (1) · Esophageal Neoplasms (1)
Female Urogenital Diseases (28) · Female Urogenital Diseases and Pregnancy Complications (28) · Kidney Diseases (28) · Male Urogenital Diseases (28) · Neoplasms (28) · Neoplasms by Site (28) · Urogenital Diseases (28) · Urogenital Neoplasms (28) · Urologic Diseases (28) · Urologic Neoplasms (28) · Adenocarcinoma (25) · Carcinoma (25) · Neoplasms by Histologic Type (25) · Neoplasms, Glandular and Epithelial (25) · Kidney Neoplasms (24)
Nivolumab (10) · Specimen Handling (10) · CTLA-4 Antigen (7) · Ipilimumab (7) · Magnetic Resonance Spectroscopy (6) · cabozantinib (5) · Biopsy (4) · pembrolizumab (4) · Axitinib (3) · Blood Specimen Collection (2) · Everolimus (2) · Radiopharmaceuticals (2) · Sunitinib (2) · lenvatinib (2) · 2-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid (1)
City of Hope Medical Center (4) · M.D. Anderson Cancer Center (3) · Centre Leon Berard (2) · Mayo Clinic (2) · SWOG Cancer Research Network (2) · University of Texas Southwestern Medical Center (2) · Vanderbilt-Ingram Cancer Center (2) · Abramson Cancer Center at Penn Medicine (1) · Academic and Community Cancer Research United (1) · Arcus Biosciences, Inc. (1) · Eli Lilly and Company (1) · European Organisation for Research and Treatment of Cancer - EORTC (1) · Fred Hutchinson Cancer Center (1) · Fudan University (1) · Jinling Hospital, China (1)
United States (25) · France (5) · China (3) · Australia (2) · Canada (2) · Netherlands (2) · New Zealand (2) · Argentina (1) · Czechia (1) · Germany (1) · Italy (1) · Japan (1) · Poland (1) · Romania (1) · Singapore (1)
Sumanta K Pal (3) · Raquibul Hannan, MD, PhD (2) · Alex Chehrazi-Raffle, MD (1) · Ana Aparicio (1) · Andrew W Hahn, MD (1) · Brian A. Costello, MD (1) · Brian I Rini, MD (1) · Brian Rini (1) · Charles B Nguyen (1) · David Y Oh, MD, PhD (1) · Dev Mukhopadhyay, PhD (1) · Emmanuel Seront, MD (1) · Freddy Escorcia, MD, PhD (1) · Heying Duan, MD (1)
PMID 26706103, PMID 27154357, PMID 33742979, PMID 35310961, PMID 38302933, PMID 38942995, PMID 40212021, PMID 40791544, PMID 41073165, PMID 41484629, PMID 42246926
P30CA033572 (5), K12CA270377 (1), P30CA015083 (1), P30CA068485 (1), U10CA180888 (1)